Calla Lily Clinical Care, a women’s health-focused medical technology company, has joined Wellcome Leap’s Focused Antibiotics programme – a new $50m funded programme to transform how antibiotics are delivered and address the growing global threat of antimicrobial resistance (AMR). Founded by the Wellcome Trust in 2020, US non-profit Wellcome Leap… Read More
Researchers have identified chemical compounds derived from a fungus that could help treat an aggressive cancer, the Journal of Antibiotics reports. The compounds, named paramyfurans A and B and paramylactone, were extracted from a fungal strain called Paramyrothecium sp. BF-1049. They were tested against three mesothelioma cell lines in a laboratory setting, with… Read More
This is the latest episode of the free DDW Narrated Podcast. The episode covers two articles written for DDW Volume 25, Issue 2, Spring 2024. The first article is called ‘Why more work is needed to fight antimicrobial resistance’. In the article, DDW Editor Reece Armstrong speaks to Professor… Read More
A commonly prescribed antibiotic could help reduce the risk of some young people developing schizophrenia, new research suggests. Experts found that patients of adolescent mental health services who were treated with the antibiotic doxycycline were significantly less likely to go on to develop schizophrenia in adulthood compared… Read More
PACE, one of the UK’s largest public-private initiatives targeting early-stage antimicrobial drug and diagnostic development, has launched its third round of funding to support innovative projects. The initiative has announced £6 million ($8 million) in funding for antibacterial treatment innovations, aiming to tackle resistant bacterial infections and… Read More
This is the latest episode of the free DDW narrated podcast, titled “Strategies and challenges in therapeutic development and lab practice”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “The inner workings of antibiotics”, “Targeting advances in immunotherapies”, and… Read More
An investment of $1 billion to increase access to innovative antibiotics and high-quality treatment of antimicrobial resistance (AMR), could boost the European Union’s (EU) economy by $88 billion a year, by the year 2050. This is according to new research from the Center for Global Development, the… Read More
Understanding the precise mechanism behind bacterial cell division can help in the development of targeted ways to inhibit bacterial proliferation. To this end, researchers in Japan have explored the structure and molecular basis of the interaction between bacterial cell division-associated proteins FtsZ and ZapA. Cell… Read More
Scientists from the UK and South Africa have discovered a surprising new role for a commonly-used antibiotic that could open the door to a new family of improved therapies for high blood pressure and cardiovascular disease. The international team, led by Professor Ravi Acharya from the University… Read More
Newly published Phase III trial results suggest the new antibiotic gepotidacin could treat uncomplicated urogenital gonorrhoea (GC). The trial showed that gepotidacin was non-inferior with 92.6% success rates when compared to 91.2% success rates for intramuscular ceftriaxone plus oral azithromycin combined therapy, a leading combination treatment… Read More
The US Food and Drug Administration (FDA) has approved Blujepa (gepotidacin) for the treatment of female adults (≥40 kg) and paediatric patients (≥12 years, ≥40kg) with uncomplicated urinary tract infections (uUTIs). It is approved to treat infections caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae,… Read More
Scientists have developed a DNA sequencing approach that can be implemented in hospitals to diagnose bacterial infections faster and more accurately. Developed by a UK team from Barts Health NHS Trust and the Medicines and Healthcare products Regulatory Agency (MHRA), the service is designed to help doctors… Read More
Glox Therapeutics has been awarded a share of the £3 ($3.6) million funding from the Collaborative Discovery Programme (CDP), launched by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate with funding from LifeArc. Glox Therapeutics will receive up to £500,000 of the fund to accelerate the development… Read More
MicuRx Pharmaceutical’s anti-infection drug MRX-5 has been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA) for the treatment of non-tuberculous mycobacteria (NTM) infections. MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria… Read More
NTC has shared positive results from the Phase II MIRAKLE study evaluating the efficacy and tolerability of NTC014 (quinolone antibiotic + NSAID in eye drops solution) in the treatment of bacterial conjunctivitis in adults. The results show the non-inferiority of NTC014 eye drops vs. antibiotic alone in… Read More
In this webinar, hosted by DDW and supported by Thermo Fisher Scientific, you will learn about the current advancements taking place in antibiotic drug discovery. This event will highlight how cryo-electron microscopy (cryo-EM) can be used to target the lipopolysaccharide transporter MsbA in multidrug-resistant Acinetobacter… Read More
